New Trials Gives Hope for Tuberculosis Vaccine

Susan Farley
Published Online: Thursday, April 1, 2004

A new vaccine for tuberculosis (TB) will soon undergo the first phase of human safety testing. The first of its kind to be tested in the United States in the last 60 years, the new vaccine combines 2 TB proteins that stimulate a strong response by the human immune system. Researchers were able to identify these proteins from blood samples of people who never got TB despite being infected with Mycobacterium tuberculosis bacteria. These proteins were fused using recombinant DNA technology and then combined with substances that would further boost an immune system's response to the vaccine. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, remarked, "This candidate vaccine ... offers hope for reducing the burden of a disease that claims approximately 2 million lives each year."



Latest Articles
This weekly video program highlights the latest in pharmacy news, product news, and more.
Propranolol is red, digoxin is blue. Your pharmacist’s heart may skip a beat if they get a valentine from you.
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Latest Issues
$auto_registration$
VSEO N/A